Given that IL-6 adversely impacts the prognosis in patients with pancreatic cancer, blocking the IL-6 signaling pathway has been proposed as a potentially effective strategy for those with advanced PDAC [32]. Here, IL6 is linked to familial pancreatic carcinoma.